Applikon Biotechnology - DCVMN

36
Biosafety in upstream bioprocessing Erik Kakes, Sales & Marke;ng director Applikon Biotechnology

Transcript of Applikon Biotechnology - DCVMN

Page 1: Applikon Biotechnology - DCVMN

BiosafetyinupstreambioprocessingErikKakes,Sales&Marke;ngdirectorApplikonBiotechnology

Page 2: Applikon Biotechnology - DCVMN

AboutErikKakes•  StudiedBiochemistry•  Ac;veinbioreactordesignsince1988

–  Projectmanager–  Productdevelopment– Marke;ng&Sales

•  Co-ownerofApplikonBiotechnologysince2008

Page 3: Applikon Biotechnology - DCVMN

ApplikonBiotechnology•  Oneofthelargestprivatelyownedbioreactorcompanies•  Startedin1974byJanvanBurg•  Keywords:

–  Reliable–  Newtechnologies–  Longtermcustomerrela;on–  Microscaletoproduc;onscalesystems–  Localexpertsforsales,serviceandsupport–  Bioreactorsystemsonly

•  DaughtercompaniesinNetherlands,UK,USA,ChinaJanvanBurg

Page 4: Applikon Biotechnology - DCVMN

Applikonhistoryinvaccineproduc;on•  1970’s:Bilthovenunits

Dr.vanHemert&Ir.vanWezel

•  1989ApplikonandContactFlowmerger

•  1990’s:ChinaVaccineProjectRIVM,DHV,Applikon

•  Last30yearsMul;plelargescalevaccineprojects

Page 5: Applikon Biotechnology - DCVMN

Laboratorybioreactors

Page 6: Applikon Biotechnology - DCVMN

Produc0onsystems

Page 7: Applikon Biotechnology - DCVMN

• 

• Applikon Inside! SingleUsesystems

Page 8: Applikon Biotechnology - DCVMN

Phase4

Pilotmanufacturing,QC&QA

Clinical&Regulatory

Techtransfer

Pharmacovigilance

LeadDevelopment

Preclinical Phase1 Phase2 Phase3 ProductLicensure

Process&AssayDevelopment,Scale-up

Animalmodels

Discovery

QA/QPoversightincludingCMOs,CROs

CMCProjectmanagement

Facilitydevelopment(Seenextdetailslide)

VaccineDevelopment

Page 9: Applikon Biotechnology - DCVMN

CommercialManufacturing,QC&QA

Plantdesign&engineering

Procurement

QualitySystemsdevelopment

FacilityConstruc0on

EquipmentDelivery

Comple0onandcommissioning

Techtransferandvalida0on

Projectmanagement,ProjectQAandcompliancemanagement

FactoryLicencing

Qualifica0on

Recruitment&training

Techtransfer

Phase4Phase3 ProductLicensure

FacilityDevelopment

Page 10: Applikon Biotechnology - DCVMN

BiosafetyvsGMP•  Biosafety

–  Protecttheoperator•  GMP

–  Protecttheconsumer

Keepthemin Keepthemout

Page 11: Applikon Biotechnology - DCVMN

Biosafety•  Responsibilityofsupplier&customer•  Customer:

–  Providesafeenvironmentforpersonnel

–  Informsupplierofpoten;alrisks•  Supplier:

–  Intrinsicsafetyasadesigncriterium–  Understandandminimizetheprocessrisks

•  Communica;oniskey

Page 12: Applikon Biotechnology - DCVMN

Projectcommunica;on:Website•  Openinforma;onexchange•  24/7accessible•  Up-to-dateinforma;on•  Documentedcommunica;on•  Documenteddecisions•  Everybodyworkswiththesamedocuments

•  Nosurprises

Page 13: Applikon Biotechnology - DCVMN

Recap: Bioreactor

Hea;ng/coolingmedium:TOJACKET

Hea;ng/coolingmedium:FROMJACKET

GasOut

Sampling

DownStream

=RiskArea

Page 14: Applikon Biotechnology - DCVMN
Page 15: Applikon Biotechnology - DCVMN

Biosafety:Single-UseorRe-Usable•  Single-Use

–  Shortlead;me–  Lowerini;alinvestment– Moreflexibility– Moremanuallaborsomoreproceduresrequired

•  Re-Usable–  Longerlead;me–  Higherini;alinvestment–  Lessflexibility– Moreautoma;on

Page 16: Applikon Biotechnology - DCVMN

Biosafety:Single-Usebioreactors–  ReportApril2016,DutchCommissionforGene;cModifica;on

•  Integritytestofbagnotstandardized•  Biggestriskisduringinstalla;onwheremanualmanipula;onisthehighestrisk

•  Noreliableintegritytestpossibleaferinstalla;on

•  Increasedriskforoperator•  Con;nuoustrainingprogramsareneeded

Page 17: Applikon Biotechnology - DCVMN

Biosafety:Re-Usablebioreactors•  Benefitsofprocessautoma;on

–  Lessmanualmanipula;on–  Automatedtestprocedures–  Automateddocumenta;on–  Interlocksforincreasedsafety–  Verifiedautomatedtransferbetweenunits–  Con;nuousfeedbackloops

Page 18: Applikon Biotechnology - DCVMN

Recap: Bioreactor Biosafety

Hea;ng/coolingmedium:TOJACKET

Hea;ng/coolingmedium:FROMJACKET

GasOut

Sampling

DownStream

=RiskArea

No virus to exit

No virus to exit

No virus to exit No virus to exit

No virus to exit uncontrolled

No virus to exit uncontrolled

No virus to exit

No virus to exit

Page 19: Applikon Biotechnology - DCVMN

Recap: Bioreactor GMP

Hea;ng/coolingmedium:TOJACKET

Hea;ng/coolingmedium:FROMJACKET

GasOut

Sampling

DownStream

=RiskArea

No contaminant to enter

No contaminant to enter

Well defined materials

Homogeneous mixing

Defined gas supply

No contaminant to enter

No organisms to enter or exit uncontrolled

No organisms to enter or exit uncontrolled

Reproducible & Controlled conditions No organisms to enter or exit uncontrolled No contaminant to enter

Page 20: Applikon Biotechnology - DCVMN

Gas Filters

Off-gas Incinerator

Page 21: Applikon Biotechnology - DCVMN

•  0.2micrometerporesize•  Membranefilter•  Integritytestpoints•  Testintegritybeforeandaferprocess

Exhaustgasfilter

Page 22: Applikon Biotechnology - DCVMN

Exhaustgasincinerator

•  Temperaturemeasurement&Control•  Time&heatkill,con;nuousmonitoring•  200˚C,Upto200l/min

Page 23: Applikon Biotechnology - DCVMN

Agitatorsealing•  Magne;ccoupling•  Nodirectcontactbetweeninsideand

outsideofreactor•  Minimalmaintenance•  Upto40Nmtorque•  Cellcultureupto3000litervolume•  Microbialupto500litervolume

Page 24: Applikon Biotechnology - DCVMN

Equipmentriskmanagement•  Focusontheinterfaces!!!

–  Differentsuppliers•  Building,upstreamanddownstreamequipment

–  Differentequipment•  Liquidflowpath,connec;ontypes,temperatures,flows

–  Differentsofwaresolu;ons•  Handshakesbetweendevices,communica;onanddataintegra;on,valida;on,unifiedoperatorinterfaces

•  Useasmanystandardbuildingblocksaspossible–  Provenperformance

Page 25: Applikon Biotechnology - DCVMN
Page 26: Applikon Biotechnology - DCVMN

Hazopstudy•  WhatisHazop?

– Hazardandoperabilitystudy– astructuredandsystema;cexamina;onofacomplexplannedorexis;ngprocessoropera;oninordertoiden;fyandevaluateproblemsthatmayrepresentriskstopersonnelorequipment

Page 27: Applikon Biotechnology - DCVMN
Page 28: Applikon Biotechnology - DCVMN
Page 29: Applikon Biotechnology - DCVMN
Page 30: Applikon Biotechnology - DCVMN

Hazopstudyreport

Page 31: Applikon Biotechnology - DCVMN

Hazopra;ng

Page 32: Applikon Biotechnology - DCVMN

Hazopac;onlist

Page 33: Applikon Biotechnology - DCVMN
Page 34: Applikon Biotechnology - DCVMN
Page 35: Applikon Biotechnology - DCVMN

Resuming•  Biosafetyisasharedresponsibility•  Advancedautoma;onimprovessafety•  Buildintrinsicsafetyintodesign•  Hazopanalysisiden;fiesproblemsandsolu;ons•  Hazopcanbedoneonoldandnewinstalla;ons

Page 36: Applikon Biotechnology - DCVMN

Thankyou!